Follicular lymphoma · 12 regimens
Cost vs Efficacy · 8 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bevacizumab and Rituximab Variant #01 | — | R 173 472 | 84d | ~20.7 mo | — | ~8 | ~R 1 387 779 PFS proxy · indirect | 1 |
Obinutuzumab monotherapy Variant #03 | — | R 166 941 | 21d | — | — | — | — | — |
Zanubrutinib and Obinutuzumab (ZO) Variant #01 | — | R 161 145 | 28d | — | — | — | — | — |
Lenalidomide and Rituximab (R2) Variant #10 | — | R 86 746 | 35d | ~26.7 mo | — | ~24 | ~R 2 081 899 PFS proxy · indirect | 4 |
Bortezomib and Rituximab (VR) Variant #06 | — | R 64 235 | 35d | ~12.8 mo | — | ~12 | ~R 770 814 PFS proxy · indirect | 1 |
R-CHOP Variant #23 | — | R 59 865 | 21d | ~44.4 mo | — | ~65 | ~R 3 891 219 PFS proxy · indirect | 3 |
Copanlisib and Rituximab Variant #01 Partial | — | R 58 980 | 28d | ~21.5 mo | — | ~24 | ~R 1 415 508 PFS proxy · indirect | 1 |
R-FCM Variant #04 | — | R 46 093 | 42d | — | — | — | — | — |
Bendamustine and Rituximab (BR) Variant #12 | — | R 40 807 | 28d | — | — | — | — | 1 |
Ibritumomab tiuxetan protocol Variant #18 | — | R 27 524 | 8d | ~36.5 mo | — | ~139 | ~R 3 825 804 PFS proxy · indirect | 1 |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | ~30.8 mo | — | ~11 | ~R 69 973 PFS proxy · indirect | 2 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~11.0 mo | — | ~2 | ~R 104 PFS proxy · indirect | 6 |
12 of 12 regimens shown